Browse by author
Lookup NU author(s): Professor Jelena Mann, Aidan Maxwell, Professor Fiona OakleyORCiD, Professor Derek Mann
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background & Aims: Myofibroblast transdifferentiation generates hepatic myofibroblasts, which promote liver fibrogenesis. The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a negative regulator of this process. We investigated epigenetic regulation of PPAR gamma and myofibroblast transdifferentiation. Methods: Chromatin immunoprecipitation (ChIP) assays assessed the binding of methyl-CpG binding protein 2 (MeCP2) to PPAR gamma and chromatin modifications that silence this gene. MeCP2(-/y) mice and an inhibitor (DZNep) of the epigenetic regulatory protein EZH2 were used in the carbon tetrachloride model of liver fibrosis. Liver tissues from mice were assessed by histologic analysis; markers of fibrosis were measured by quantitative polymerase chain reaction (qPCR). Reverse transcription PCR detected changes in expression of the microRNA miR132 and its target, elongated transcripts of MeCP2. Myofibroblasts were transfected with miR132; PPAR gamma and MeCP2 expressions were analyzed by qPCR or immunoblotting. Results: Myofibroblast transdifferentiation of hepatic stellate cells is controlled by a combination of MeCP2, EZH2, and miR132 in a relay pathway. The pathway is activated by down-regulation of miR132, releasing the translational block on MeCP2. MeCP2 is recruited to the 5' end of PPAR gamma, where it promotes methylation by H3K9 and recruits the transcription repressor HP1 alpha. MeCP2 also stimulates expression of EZH2 and methylation of H3K27 to form a repressive chromatin structure in the 3' exons of PPAR gamma. Genetic and pharmacologic disruptions of MeCP2 or EZH2 reduced the fibrogenic characteristics of myofibroblasts and attenuated fibrogenesis. Conclusions: Liver fibrosis is regulated by an epigenetic relay pathway that includes MeCP2, EZH2, and miR132. Reagents that interfere with this pathway might be developed to reduce fibrogenesis in chronic liver disease.
Author(s): Mann J, Chu DCK, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, Mann DA
Publication type: Article
Publication status: Published
Journal: Gastroenterology
Year: 2010
Volume: 138
Issue: 2
Pages: 705-714
ISSN (print): 0016-5085
ISSN (electronic): 1528-0012
Publisher: W.B. Saunders Co.
URL: http://dx.doi.org/10.1053/j.gastro.2009.10.002
DOI: 10.1053/j.gastro.2009.10.002
Altmetrics provided by Altmetric
